| Proposal number |
Study Sponsor(s) |
Title |
Institution |
Lead researcher |
|
| 611 | GSK | Long-acting beta2-agonists for chronic obstructive pulmonary disease | Cochrane Airways Group, at St George's University of London | Kayleigh Kew | Further Details |
| 628 | GSK | Predictive and Prognostic Value of Blood Cell Ratios in Patients with Metastatic Renal Cell Carcinoma Treated with Pazopanib | Divisions of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, Toronto, Canada | Arnoud J. Templeton, MD | Further Details |
| 631 | GSK | Predictors of BPH Progression | Duke University | Dr. Stephen Freedland, MD | Further Details |
| 637 | GSK | Relationship of Activated Clotting Time and Bleeding Related Outcomes in the FUTURA OASIS-8 Trial | New York University school of Medicine, NY, NY | Sripal Bangalore | Further Details |
| 639 | GSK | Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux in Patients with Peripheral Arterial Disease | St Luke's-Roosevelt Hospital of the Columbia University of Physicians and Surgeons | Saurav Chatterjee MD | Further Details |
| 645 | GSK | The Influence of Age, Gender, and Race on the Effects of Combination Therapy with Carvedilol plus Lisinopril Versus Lisinopril Monotherapy for Systemic Hypertension | New York Medical College-Metropolitan Hospital Center, Department of Medicine, New York, NY | Partha Sardar | Further Details |
| 646 | GSK | Factors influencing immune response and patient outcomes following influenza vaccination. | Health Protection Research Group, University of Nottingham | Dr Subhadra Rajanaidu | Further Details |
| 647 | GSK | Assessing and Reporting Heterogeneity of Treatment Effect in Randomized Clinical Trials | Institute for Clinical Research and Health Policy Studies, Tufts Medical Center | David M. Kent, MD, MSc | Further Details |
| 651 | GSK | Descriptive evaluation of SAE reporting rates in vaccine clinical trials among Latin American children. | P95 Pharmacovigilance and Epidemiology Services | Thomas Verstraeten | Further Details |
| 653 | GSK | Functional Estimation of Interventional Effects | Department of Economics, Indiana University, Bloomington, Professor
Sungkyunkwan University, Professor of Economics | Joon Park | Further Details |
| 654 | GSK, ViiV | Development of Population Pharmacokinetic/Pharmacodynamic Models for Pazopanib within the EuroTARGET project (Workpackage 7) | Institute of Pharmacy, Clinical Pharmacy, University of Bonn, Germany | Ulrich Jaehde | Further Details |
| 657 | GSK | Use of Heparins in patients with Cancer: Individual patient-data meta-analysis of randomized trials | McMaster University | Holger Schunemann, MD, MSc, PhD | Further Details |
| 668 | GSK | Associations between antihypertensive drugs and patterns of blood pressure changes: a strategy to reduce the burden of anti-VEGF induced hypertension | Flinders University, School of Medicine, Adelaide, Australia; Southern Adelaide Health Network, Adelaide, Australia | Arduino A Mangoni | Further Details |
| 669 | GSK | A multi-center, double-blind, placebo controlled study of paroxetine and imipramine in adolescents with unipolar major depression - efficacy and adverse outcomes. | University of Adelaide | Jon Jureidini | Further Details |
| 672 | GSK | The Development of Toxicity Prediction Tools to Assist Oncologists in the Management of Adverse Events in Patients Receiving Treatment with Lapatinib | Memorial Sloan-Kettering Cancer Center | Dr. Mario Lacouture | Further Details |
| 674 | GSK | Antiepileptic drug monotherapy for epilepsy: an overview of systematic reviews andnetwork meta-analysis | University of Liverpool | Antony Marson | Further Details |
| 675 | Novartis | Validation study on magnitude of tumorshrinkage as a prognostic marker | Medical School Hannover
Hematologgy, hemostasis, oncology and stemcelltransplantation
Carl-Neuberg-Str. 1
30627 Hannover, Germany | Viktor Grünwald | Further Details |
| 679 | GSK | An Epigenetic Analysis of the ALOX5 Gene Related to the Clinical Response to Montelukast | University of North Carolina at Chapel Hill
Division of Pulmonary and Critical Care Medicine
130 Mason Farm Rd
Chapel Hill NC 27599-7020 | Wayne H Anderson | Further Details |
| 681 | GSK | A randomized, double blind, placebo-controlled trial to evaluate the effect of rosiglitazone on metabolic markers in psoriasis patients | Massachusetts General Hospital | Alexa B. Kimball | Further Details |
| 911 | GSK | Outcome Measures in Systemic Lupus Erythematosus: Constructing a Meaningful Response Index from Existing Clinical Trial Data | Cedars-Sinai Medical Center | Lindsy Forbess, MD, MSc | Further Details |
| 918 | GSK | Outcomes after Percutaneous Coronary Intervention in Cancer patients with Acute Coronary Syndrome | New York Medical College, New York, NY. | Partha Sardar MD | Further Details |
| 928 | GSK | Lung function and airway inflammation response after ozone exposure 0.25ppm | UNC Hospitals | Krista Todoric, MD | Further Details |
| 930 | GSK | MASTERMIND: Stratification of glycaemic response the ADOPT and RECORD studies | NIHR Exeter Clinical Research Facility
University of Exeter Medical School
Barrack Road
Exeter
EX2 5DW | Professor Andrew Hattersley, M.D. FRS | Further Details |
| 945 | ViiV | THE CD4/CD8 RATIO AS A PREDICTOR OF NON-AIDS EVENTS DURING ANTIRRETROVIRAL THERAPY: CONFIRMATION OF ITS PREDICTIVE VALUE AND IMPACT OF MARAVIROC IN TREATMENT-EXPERIENCED PATIENTS | University Hospital Ramón y CAjal | Santiago Moreno | Further Details |
| 946 | GSK | Assessing models for changes in tumour size over time and how they relate to survival times. | Division of Mathematics, University of Dundee, Dundee, UK. | Raluca Eftimie | Further Details |
| 951 | GSK | Optimized Eltrombopag Treatment of Hepatitis C virus-related thrombocytopenia | The University of Jordan | Mohammad Saleh | Further Details |
| 955 | GSK | A study of subgroup identification and micro aggregation | National Institute of Statistical Sciences
www.niss.org | S. Stanley Young | Further Details |
| 956 | Roche | Bone Quality Project | University of California, San Francisco | Dennis M. Black | Further Details |
| 976 | GSK | 5-alpha reductase inhibitor use and risk of lung cancer | Department of Internal Medicine
University of Manitoba
Department of Medical Oncology and Hematology
Cancercare Manitoba | Marshall Pitz | Further Details |
| 977 | GSK | The implication of central adjudication of COPD exacerbations by experts for treatment effect estimates and sample size calculation | University of Zurich
Institute of Social and Preventive Medicine
Hirschengraben 84
CH-8001 Zurich | Milo Puhan | Further Details |
| 980 | GSK | Association of leukotriene C4 synthase gene (rs730012, -444 A/C) polymorphism with response to leukotriene modifiers treatment in asthma patients | Institute of Epidemiology and Preventive Medicine, National Taiwan University.
Department of Family Medicine, Renai Branch, Taipei City Hospital | Yi-Fan Wu | Further Details |
| 982 | ViiV | Pharmacokinetic modeling of dolutegravir in HIV patients. | National Brain Research Centre,Manesar,Haryana,Gurgaon,India-122050 | V P Subramanyam Rallabandi | Further Details |
| 988 | Roche | PhD Project: Bayesian Multivariate Network Meta-Analysis of Ordered Categorical Data | School of Health and Related Research (ScHARR) at the University of Sheffield | Fabrizio Messina | Further Details |
| 989 | GSK | Assessing at the participant level the applicability of clinical trials to a specific patient | Lister Hill National Center for Biomedical Communications, US National Library of Medicine, NIH | Amos Cahan | Further Details |
| 993 | GSK | A Spirometric Z-Score Based Reappraisal of the TORCH Study(GSK-SCO30003): Salmeterol and Fluticasone Propionate in COPD. | Yale University School of Medicine | Carlos A. Vaz Fragoso, MD | Further Details |
| 995 | Boehringer Ingelheim, GSK, Lilly, Roche, Takeda, UCB | Identifying immune modulating patterns across diseases from open clinical trial data | Institute for Computational Health Sciences
UCSF School of Medicine
Mission Hall - 550 16th St, San Francisco, CA 94158
email:Atul.Butte@ucsf.edu
Phone: 415-514-0511 | | Further Details |
| 997 | GSK | Predictors of Prostate Cancer Progression Among Men on Active Surveillance | Duke University | Stephen Freedland, MD | Further Details |
| 998 | GSK | Determination of minimally important difference for short form 36 and Facit Fatigue for Systemic lupus erythematosus | Rush University Medical Center | Meenakshi Jolly, MD, MSCP | Further Details |
| 999 | Boehringer Ingelheim, GSK | Assessing the Comparative Efficacy of Therapeutics for Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of Randomized Trials | Thomson Reuters | Kristen M Sweet | Further Details |
| 1000 | GSK | Review of fever and febrile convulsion rates in children after trivalent influenza vaccine. | National Centre for Immunisation Research and Surveillance, The Children’s Hospital at Westmead | Dr Jean Li-Kim-Moy, MBBS, FRACP | Further Details |
| 1002 | GSK | Long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary disease | Kansas City University of Medicine & Biosciences | Michael Sarai | Further Details |
| 1013 | GSK | Biopsy Avoidance in Patients At Risk For Prostate Cancer and in Patients With Low Risk Prostate Cancer: Developing Tools for Personalized Medicine | Princess Margaret Cancer Centre, University Health Network, Surgical Oncology, Urologist. | Girish Kilkarni, MD, PhD | Further Details |
| 1015 | GSK | Pazopanib induced liver toxicity: incidence, pathogenesis and value of liver enzymes increase as a predictor of outcome in metastatic soft tissues sarcoma patients. A retrospective multi-centric study | Department of Medical Oncology
University Campus Bio-Medico
Via A. Del Portillo 200, 00128
Rome, Italy | Bruno Vincenzi, MD, PhD | Further Details |
| 1016 | GSK | Statistical methods for estimating the duration of protection of malaria vaccines: secondary analysis of data from the RTSS/AS02A trial in Mozambique. | London School of Hygiene and Tropical Medicine | Paul Milligan | Further Details |
| 1020 | GSK | Genomic prediction tools developed using phenotypes from disease progression models | University of Chicago | Manish Sharma, MD | Further Details |
| 1022 | Novartis | Prediction of maximal work load (Wmax)in a bicycle test in patients with COPD. | Dept of Respiratory Medicine & Allergology
Lund University Hospital
22185 Lund, Sweden | Göran Eriksson | Further Details |
| 1028 | ViiV | Impact of dolutegravir on CD4+/CD8+ ratio and CD4+ percentage in HIV-infected naive patients. | Hospital San Pedro - Center for Biomedical Research of La Rioja (CIBIR), SPAIN | José Ramón Blanco | Further Details |
| 1053 | GSK | Validation of the spirometric LMS equations in the Spanish population | Respiratory department, Universitary Hospital of Araba | Dr. Patricia Sobradillo | Further Details |
| 1057 | GSK | Health-related utility and disutility value in metastatic renal cell carcinoma patient treated with pazopanib | Department of Urology, Seoul National University Hospital, College of Medicine Seoul National University | Chang Wook Jeong | Further Details |
| 1058 | ViiV | Ritonavir-boosted protease inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimens: a systematic review and individual patient data me | Centre for Health & Infectious Diseases Research
Rigshospitalet, University of Copenhagen
CHIP, Department of Infectious Diseases and Rheumatology,
Section 2100, Finsencentret
Blegdamsvej 9
DK-2100 Copenhagen Ø
Denmark | Alvaro H Borges | Further Details |
| 1071 | Boehringer Ingelheim, GSK | Optimising the Analysis of vascular Prevention trials (OA-Prevention) | University of Nottingham | | Further Details |
| 1073 | GSK | End-of-life trajectories in COPD | CIRO+, centre of expertise for chronic organ failure; Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands | Dr. Daisy J.A. Janssen | Further Details |
| 1075 | Roche | Efficacy and Safety of Bevacizumab in the Elderly Cancer Patients: Pooled Analysis of Ten Randomized Clinical Trials | Department of Biostatistics & Bioinformatics
Duke University | Xiaofei Wang | Further Details |
| 1078 | Lilly | Nocebo effects in the treatment of bipolar disorder: Results from an individual study participant level meta-analysis of the placebo arm of olanzapine clinical trials | University Hospital Geelong, Australia | Seetal Dodd | Further Details |
| 1079 | ViiV | The effects of maraviroc versus efavirenz in combination with zidovudine/abacavir on the CD4/CD8 ratio in treatment-naïve HIV-infected individuals. | Deparment of Infectious Diseases, University Hospital Ramón y Cajal, Madrid, Spaon. | Sergio Serrano-Villar, MD PhD | Further Details |
| 1084 | GSK | Studies on the relationship between corticosteroids and unfavorable medical effects. A study based on the BLISS-52 and BLISS-76 clinical trials. | Karolinska Institutet
Department of Medicine
Unit for Clinical Therapy Research, Inflammatory Diseases
(ClinTRID), D1:00, Karolinska University Hospital, Stockholm, Sweden | Ronald van Vollenhoven, MD, PhD | Further Details |
| 1085 | Roche | Optimized peg-interferon alpha-2a Treatment of Hepatitis C and Hepatitis B | The University of Jordan | Mohammad I Saleh, PhD | Further Details |
| 1086 | ViiV | Abacavir HLA-B*57:01 tolerance and genetic variation within the MHC. | Institute for Immunology & Infectious Diseases, Discovery Way, Murdoch, WA 6150 | Elizabeth Phillips, MD | Further Details |
| 1088 | GSK | A study to identify risk factors that modify Rotarix efficacy and influence the time to rotavirus gastroenteritis among vaccinated and unvaccinated African infants. | University of North Carolina at Chapel Hill | Joann Gruber | Further Details |
| 1090 | GSK | Validating the test-negative case-control design for estimating rotavirus vaccine effectiveness using gold-standard randomized controlled trial data from South Africa and Malawi (Rota-037) | Fred Hutchinson Cancer Research Center;
Department of Biostatistics, University of Washington | M. Elizabeth Halloran | Further Details |
| 1100 | Boehringer Ingelheim | Systolic blood pressure level and risk of intracerebral hemorrhage. | Julius Center for Health Sciences and Primary Care
UMC Utrecht | Jacoba P Greving | Further Details |
| 1103 | GSK | A study on the possible association between antidepressant response to SSRIs and proneness for side effects | Department of Pharmacology, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden | Elias Eriksson, MD, PhD | Further Details |
| 1108 | GSK | Correlation between SF-36 PCS and MCS scores and SELENA SLEDAI activity score in SLE: a meta-anaysis. | Division of Clinical Immunology and Allergy, Department of Internal Medicine Specialties, University Hospital and School of Medicine, Geneva, Switzerland | Chaigne Benjamin | Further Details |
| 1125 | Lilly | Initial severity and efficacy of antipsychotics for schizophrenia and bipolar mania: Individual participant level analyses of placebo-controlled studies. | Department of Psychiatry and Psychotherapy TU-München | Stefan Leucht | Further Details |
| 1128 | GSK | EuroTARGET GWAS on sunitinib pharmacogenetics in patients with metastatic renal cell carcinoma | Leiden University Medical Center (LUMC) | Prof. H.J. Guchelaar | Further Details |
| 1130 | GSK, UCB | Factors that determine placebo response in epilepsy trials | Center for Biostatistics
Department of Population Health Science and Policy
Icahn School of Medicine at Mount Sinai
One Gustave Levy Place, Box 1077
New York, NY 10029 | Emilia Bagiella | Further Details |
| 1132 | GSK | Cytokine patterns in anti-viral disease vaccines: a knowledge driven approach | Division of Systems Medicine Chief
Department of Pediatrics
Stanford University | Atul J. Butte, MD, PhD | Further Details |
| 1134 | GSK | Incidence rate and risk factors associated with Hepatocellular carcinoma development in patients with Chronic Hpatitis C and severe thrombocytopenia: the lesson from Enable studies | AO FBF e Oftalmico, Milano Italy | Prof. Savino Bruno, MD | Further Details |
| 1136 | Takeda | Can Machine Learning Algorithms using General Labs Predict Clinical Remission and Mucosal Healing for Patients on Vedolizumab? | University of Michigan | Peter Higgins | Further Details |
| 1137 | GSK | Immunotherapy trial simulators: Using mathematical, computational and statistical techniques to simulate trial design for new products in the treatment, vaccination and immunoprophylaxis of disease. | Imperial College London | Roy Anderson, PhD | Further Details |
| 1140 | Boehringer Ingelheim | Evaluation of the effect of incidental beta blocker use on clinical response to the EGFR TKI, afatinib | MD Anderson Cancer Center | John Heymach, MD, PhD | Further Details |
| 1141 | GSK | Multivariate methods for meta-analysis of vaccine studies with multiple correlated outcomes | Nuffield Department of Primary Care Health Sciences, University of Oxford | Merryn Voysey | Further Details |
| 1142 | Boehringer Ingelheim, GSK, UCB | A meta-analysis of Parkinson’s disease | Division of Systems Medicine
Department of Pediatrics
Stanford University | Atul Butte | Further Details |
| 1148 | Lilly | Meta-analysis of the risk of relapse in bipolar disorder | FIDMAG Germanes Hospitalàries & King’s College London | Dr. Joaquim Radua | Further Details |
| 1152 | Boehringer Ingelheim | Advanced analytic methods to refine phenotyping and risk prediction among patients with atrial fibrillation in the RE-LY trial | Yale School of Medicine
Center for Outcomes Research and Evaluation | Nihar Desai, MD, MPH | Further Details |
| 1154 | GSK | Developing New Outcome Measures for SLE by Deconvoluting Available Datasets | Lupus Research Institute | Peter E. Lipsky, MD | Further Details |
| 1157 | GSK | Quality-adjusted survival analysis for patients with metastatic renal cell carcinoma treated in a phase III trial of pazopanib versus sunitinib (COMPARZ trial) | Department of Urology, Seoul National University Hospital, College of Medicine Seoul National University | Chang Wook Jeong | Further Details |
| 1159 | ViiV | Validation of Pharmacokinetic/Viral Dynamic Modeling and Simulation using the Dolutegravir Phase IIa Dataset | University of Alabama at Birmingham | Edward P. Acosta, Pharm.D. | Further Details |
| 1160 | Boehringer Ingelheim | Development of a clinical decision support tool to identify patients at high risk of early or late bleeding complications from anticoagulation | Department of Epidemiology and Biostatistics
College of Public Health
University of Georgia
Athens, GA 30602 | Mark H. Ebell MD, MS | Further Details |
| 1161 | Roche | Novel approaches to the prediction of influenza complications | Department of Epidemiology and Biostatistics
College of Public Health
University of Georgia
Athens, GA 30602 | Mark H. Ebell | Further Details |
| 1173 | GSK, Lilly | Initial severity and antidepressant efficacy for anxiety disorders: an individual patient data meta-analysis | Interdisciplinary Center Psychopathology and Emotion regulation, Department of Psychiatry, University Medical Center Groningen, the Netherlands | Ymkje Anna de Vries | Further Details |
| 1180 | GSK | Evaluation of a platelet count threshold for bleeding risk in thrombocytopenic patients with chronic liver disease who undergo diagnostic and therapeutic invasive procedures. | Department of Internal Medicine, University of Genoa, Genoa, Italy. | Edoardo G. Giannini | Further Details |
| 1186 | GSK | Using generalized pairwise comparisons to assess the benefit/risk balance of pazopanib vs sunitinib for patients with advanced or metastatic renal cell carcinoma | IDDI inc | Marc Buyse | Further Details |
| 1206 | GSK | Efficacy of Belimumab on Mucocutaneous Involvement in Patients with Systemic Lupus Erythematosus (MUCOBEL) | Interdisciplinary Center of Clinical Trials (IZKS), University Clinic of Mainz, Germany | Kuhn, Annegret | Further Details |
| 1224 | GSK | INTERACTION BETWEEN MENINGOCOCCAL SEROGROUP B VACCINE (BEXSERO™) AND ROUTINE INFANT VACCINES ON THE RISK OF OCCURRENCE AND RECURRENCE OF ADVERSE EVENTS FOLLOWING IMMUNIZATION. | Institut National de Santé Publique du Québec(INSPQ)
and
Laval University | Gaston De Serres | Further Details |
| 1234 | Lilly | Predictors of Placebo Response in Pediatric Patients with Generalized Anxiety Disorder | University of Cincinnati | Jeffrey R. Strawn | Further Details |
| 1236 | GSK | COPERNICUS re-analysis | Magdi Yacoub Institute - Heart Science Centre
National Heart & Lung Institute (Myocardial Function Section)
Harefield Hospital
Hill End Road
Harefield, Middlesex, UB9 6JH | John Cleland | Further Details |
| 1250 | Boehringer Ingelheim, Lilly | The relationship of treatment effects and per capita income of study countries in duloxetine trials in the treatment of depressed patients | Department of Psychiatry II, Ulm University | Markus Koesters | Further Details |
| 1256 | GSK | Population mechanistic heamatotoxicity modeling of Dapsone in G6PD deficiency patients | Head of Department, Department of Clinical Pharmacology, Mahidol-Oxford Tropical Medicine research Unit (MORU) | Joel Tarning | Further Details |
| 1257 | GSK | An independent evaluation of the cardiovascular risk of rosiglitazone: meta-analysis of GSK’s publicly available clinical trial data | Yale University School of Medicine
Yale-New Haven Hospital Center for Outcomes Research and Evaluation | Joseph S. Ross, MD, MHS | Further Details |
| 1258 | Roche | Advance lung cancer inflammation index (ALI) in metastatic non-squamous lung cancer: A validation study | University of Texas, Houston, Texas, USA | Syed Hasan Raza Jafri | Further Details |
| 1273 | GSK | Post-hoc analysis of placebo-controlled trials in children and adolescents with depression | University of Gothenburg | Elias Eriksson | Further Details |
| 1277 | Roche | Immunotherapy trial simulators: Using mathematical, computational and statistical techniques to simulate trial design for new products in the treatment, vaccination and immunoprophylaxis of disease. | Imperial College London | Roy Anderson | Further Details |
| 1280 | GSK | Placebo and nocebo effects in migraine Ver 2 | University Hospitals Tuebingen
Dept. of Internal Medicine
Tuebingen, Germany | Paul Enck | Further Details |
| 1292 | Lilly | Applications of Item Response Theory to Clinical ADHD Research: Analysis of the ADHDRS-IV and Modeling Response to Treatments and Item-Level Treatment Sensitivity | University of California, Los Angeles | Alex Sturm | Further Details |
| 1293 | Roche | INCIDENCE OF BRAIN METASTASES IN METASTATIC BREAST CANCER PATIENTS RECEIVING PALLIATIVE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB: A METAANYLSIS OF FIVE PROSPECTIVE RANDOMIZED PHASE III TRIALS | Medical University of Vienna, Comprehensive Cancer Center Vienna | Rupert Bartsch | Further Details |
| 1295 | Boehringer Ingelheim | A Swapping Method Based on Covariate Classification for Average TreatmentEffect Estimation. | University of Maryland, Baltimore County (UMBC), Department of Mathematics and statistics | Dr. Bimal Sinha | Further Details |
| 1307 | Takeda | The Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus in Patients with Chronic Kidney Disease | Seven Oaks General Hospital Renal Program | Dr. Navdeep Tangri | Further Details |
| 1316 | Boehringer Ingelheim | Blinding (Masking) and the Placebo Effect | University of Michigan Medical School | James Brian Byrd, MD, MS, FAHA, FACC | Further Details |
| 1320 | GSK | Utility of a measure of Lupus Low Disease Activity State in SLE | Monash Health | Pei Xuan Ong (Emily) | Further Details |
| 1321 | GSK | Bone Quality Project | University of California, San Francisco | Dennis M. Black | Further Details |
| 1322 | GSK | Comparative efficacy of different therapeutic approaches in the "naïve" patient with chronic obstructive pulmonary disease (COPD): analysis of patient-level data | None | Giulio Pareto | Further Details |
| 1323 | Lilly | Detection of uninformative clinics during the trial of a new drug using statistical and machine learning techniques | KKT Technology pte. ltd. | Praveen Deorani | Further Details |
| 1326 | Lilly | Reliability and Validity of the Parent Rating of Evening and Morning Behavior Scale, Revised | SUNY Upstate Medical University | Steven V. Faraone, Ph.D. | Further Details |
| 1331 | Boehringer Ingelheim | Impact of baseline diabetes and obesity statuses on outcomes post-ischemic stroke | Medical University of South Carolina in Public Health Sciences | Colleen Bauza | Further Details |
| 1335 | GSK, UCB | Investigation into the natural course of epilepsy and the implications on clinical trials | NINDS, National Institutes of Health | Daniel Goldenholz | Further Details |
| 1341 | Boehringer Ingelheim | Vol-PACT: Improving Volumetric CT Metrics for Precision Analysis of Clinical Trial Results | Dana-Farber Cancer Institute
Harvard Medical School | Geoffrey R. Oxnard | Further Details |
| 1343 | GSK | Improving the Assessment of Systemic Lupus Erythematosus Disease Activity | University of Toronto,
University Health Network | Zahi Touma | Further Details |
| 1373 | GSK | An exploratory analysis of headache in placebo controlled trials of paroxetine for generalized anxiety disorder | University of Kentucky | Jonathan H. Smith, M.D. | Further Details |
| 1374 | GSK | A novel representation of vaccine efficacy trial datasets for use in computer simulation of vaccination policy | University of Pittsburgh | Michael M. Wagner | Further Details |
| 1377 | GSK | The association between patient outcomes under two treatments (ABOUT) in cross-over trials | IDDI
30 avenue provinciale
1340 Louvain-la-Neuve
Belgium | Marc Buyse, ScD | Further Details |
| 1387 | GSK | Sex-differences in immunogenicity, reactogenicity and efficacy in response to vaccines in infants and young children | Nuffield Department of Primary Care Health Sciences, University of Oxford | Merryn Voysey | Further Details |
| 1393 | Roche | Prognostic influence of body mass index and body weight gain in colorectal cancer patients treated with adjuvant chemotherapy: data from The AVANT study | Department of Internal Medicine, Seoul National University Hospital | Sae-Won Han | Further Details |
| 1401 | Sanofi | Use of Heparins in patients with Cancer: Individual patient-data meta-analysis of randomized trials | McMaster University | Holger Schunemann | Further Details |
| 1403 | ViiV | Mathematical modeling of the HIV transmission risk during the first 24 weeks after initiation of antiretroviral therapy in naïve HIV-infected MSM | Hospital General Universitario Gregorio Marañón | Juan Berenguer | Further Details |
| 1421 | GSK | Cost utility analysis comparing belimumab against rituximab in systemic lupus erythematosus | Wingate University | Chris Gillette | Further Details |
| 1422 | UCB | Developing new outcome measures for SLE by deconvoluting available data sets | LRI | Peter E. Lipsky, MD | Further Details |
| 1428 | Boehringer Ingelheim | Estimating absolute treatment effect of dabigatran 110 mg bid vs. 150 mg bid (vs. warfarin) for individual patients with atrial fibrillation. | University Medical Center Utrecht, Utrecht, the Netherlands | Frank L.J. Visseren | Further Details |
| 1430 | GSK | Comparison of various remission criteria for SLE. A study based on the BLISS-52 and BLISS-76 clinical trials. | Department of Medicine, Solna | Ronald van Vollenhoven | Further Details |
| 1433 | Boehringer Ingelheim, Lilly, Roche | Identification of patient subgroups with enhanced treatment response in RCTs with time-to-event outcomes: use of counterfactual restricted survival times. | INSERM U1153 METHODS team, Paris, France | Ludovic Trinquart | Further Details |
| 1450 | Boehringer Ingelheim, Novartis | Understanding effectiveness of new drugs in older adults shortly after market entry. | Brigham and Women's Hospital and Harvard Medical School | Shirley V Wang | Further Details |
| 1451 | GSK | Assessment of bias from treatment discontinuation on mortality and exacerbations in the Towards a Revolution in COPD Health (TORCH) randomized trial | McGill University | Samy Suissa | Further Details |
| 1452 | GSK | A study to determine if prior rotavirus exposure modifies the effect of rotavirus vaccines given to infants in low- and middle-income African countries | University of North Carolina at Chapel Hill | Sylvia Becker-Dreps | Further Details |
| 1455 | Boehringer Ingelheim | Prediction of major bleeding in atrial fibrillation patients with a history of stroke or transient ischemic attack | Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands | Jacoba Greving | Further Details |
| 1456 | ViiV | Impact of ongoing side effects on the efficacy of initial antiretroviral therapy | St Vincent's Hospital, Sydney | Andrew Carr | Further Details |
| 1457 | Lilly | Initial severity and efficacy of antipsychotics for schizophrenia and bipolar mania: Individual participant level analyses of placebo-controlled studies. | Department of Psychiatry and Psychotherapy TU-München | Stefan Leucht | Further Details |
| 1461 | Lilly | Regression discontinuity designs to evaluate real-world clinical effectiveness: a case study of drotrecogin alpha | Boston University | Allan J. Walkey | Further Details |
| 1470 | Takeda, UCB | The efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease | Gastroenterology Department, First Affiliated Hospital of Sun-YatSen University, Guangzhou, China
Director, IBD Service, Sheba Medical Center, Tel-Aviv University, Israel | Shomron Ben-Horin M.D. | Further Details |
| 1473 | Roche | Comparison of the pharmacokinetics of oral once-monthly 150mg ibandronate between ethnic Europeans and Taiwan post-menopausal osteoporotic women across two phase 1 studies | (1) Department of Laboratory Medicine, National Taiwan University Hospital
(2) Institute of Epidemiology and Preventive Medicine, National Taiwan University | Keh-Sung Tsai | Further Details |
| 1475 | Boehringer Ingelheim | Predicting safety and efficacy of afatinib treatment of NSCLC | Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, Australia | Assoc/Prof Michael Sorich | Further Details |
| 1481 | GSK | Efficacy and safety of belimumab in childhood-onset lupus | Columbia University Medical Center
630 168th St, Room PH 10-08
New York NY 10032 | Dr Anca Askanase MD, MPH | Further Details |
| 1514 | Roche | Gain of quality-adjusted life year in patients with neovascular age-related macular degeneration after anti-VEGF treatment | Department of Ophthalmology,
Seoul National University Bundang Hospital | Park, Sang Jun | Further Details |
| 1526 | GSK | Assessment of correlations among all favourable and unfavourable effects for rosiglitazone/metformin, and for metformin alone, in Type 2 diabetes. | Department of Management
London School of Economics
Houghton Street
London WC2A 2AE | Lawrence D Phillips | Further Details |
| 1528 | GSK | A Swapping Method for Average Treatment Effect Estimation | Statistics, the University of Maryland at Baltimore County (UMBC) | Bimal Sinha | Further Details |
| 1540 | GSK | IMPROVING METHODS. Our research focus is to optimize the translation of clinical trial results into clinical practice. | Brown University | Dr. Issa Dahabreh | Further Details |
| 1541 | Roche | Item calibration of the NEI VFQ-25 to improve future comparative research using patient-reported outcome (PRO) measures. | Wilmer Eye Institute
Johns Hopkins School of Medicine | Judith E. Goldstein | Further Details |
| 1542 | Boehringer Ingelheim | Optimising the Analysis of vascular Prevention trials (OA-Prevention) | University of Nottingham | Philip Bath | Further Details |
| 1558 | GSK, Novartis | Development of historical control using placebo data from pediatric epilepsy studies | UCB BioSciences, Inc
8010 Arco Corporate Drive
Suite 175
Raleigh NC 27613 | Anthony Daniels | Further Details |
| 1566 | Lilly | A microanalysis of symptoms and behaviors defining ADHD in adults and their response to both active medication and placebo | University of Utah School of Medicine Department of Psychiatry
&
Psychiatric & Behavioral Solutions LLC | Frederick W. Reimherr MD | Further Details |
| 1567 | Boehringer Ingelheim, Takeda | Stratification of SGLT2 inhibitor glucose lowering therapy in Type 2 diabetes | University of Exeter Medical Scool
(Honorary Consultant Physician (Diabetes) Royal Devon and Exeter Hospital) | Andrew Hattersley | Further Details |
| 1569 | GSK | Melancholic symptoms in bipolar depression and response to lamotrigine | Department of Psychiatry, University of Saskatchewan (U of S), Saskatchewan, Canada | Dr. Evyn Peters | Further Details |
| 1572 | Boehringer Ingelheim, Eisai, GSK, Lilly | Research to evaluate the relation of toxicity and the relative dose intensity in phase I trials beyond cycle 1 of Molecular Targeted Agents (MTAs) | Department of Breast and Medical Oncology
National Cancer Center Hospital, National Cancer Center, Japan | Kan Yonemori, MD., PhD | Further Details |
| 1575 | GSK, Lilly | Early improvement in individual symptoms and response to antidepressants in patients with major depressive disorder | Interdisciplinary Center Psychopathology and Emotion regulation, University Center of Psychiatry, University Medical Center Groningen, the Netherlands | Ymkje Anna de Vries | Further Details |
| 1581 | GSK | MASTERMIND: Assessing the cost effectiveness of a stratified approach to type 2 diabetes therapy | University of Bath | Professor Chris Jennison | Further Details |
| 1587 | Astellas | Sex-specific efficacy of mirabegron for overactive bladder (OAB) symptoms: individual patient data meta-analyses | dept. of general practice, University Medical Center Groningen, University of Groningen, the Netherlands | Marco H. Blanker, MD PhD | Further Details |
| 1593 | GSK | JANUVIA/JANUMET HTA Submission(Germany) | MSD Sharp & Dohme GmbH | Dr. Rainer Woker | Further Details |
| 1595 | Boehringer Ingelheim, GSK, Lilly, Roche | A Novel Approach to Developing Comprehensive Profile of Adverse Event (AE) Data from Clinical Trials | Cytel Statistical Software and Services Pvt. Ltd | Sharayu Paranjpe | Further Details |
| 1599 | Roche | Predictors of exposure, adverse and therapeutic effects of BRAF/MEK inhibitors in advanced melanoma. | Flinders University | Michael Sorich | Further Details |
| 1600 | Lilly | Item factor analysis of the SNAP-IV Parent Report Form: Generating item parameter estimates | University of California, Los Angeles | Alexandra Sturm, Ph.D. | Further Details |
| 1601 | Sanofi | Identification of clinical biomarkers for adjuvant chemotherapy for gastric cancer after D2 dissection by analyses of individual patents’ data from large randomized controlled trials | Chief of Surgery, JCHO Nihonmatsu Hospital
Research Professor, Fukushima Medical University | Akira Tsuburaya, MD PhD | Further Details |
| 1619 | Boehringer Ingelheim | Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke: reanalysis of ECASS III trial to assess robustness of findings across statistical models | EBSCO Information Services | Brian S. Alper, MD, MSPH, FAAFP | Further Details |
| 1622 | ViiV | A systematic literature review and Individual patient-level data enhanced network meta-analysis to determine the comparative efficacy and safety of first-line HIV antiretroviral therapies | School of Population and Public Health | Steve Kanters | Further Details |
| 1624 | Lilly | A Meta-analysis of Tardive Dyskinesia Rates in Studies Comparing Second Generation Antipsychotics (SGAs) with each other or to First-Generation Antipsychotics (FGAs). | The Zucker Hillside Hospital | Christoph U Correll | Further Details |
| 1626 | GSK | Factors associated with Prostate Cancer in Prostate Needle Biopsy | University of Illinois at Chicago | Daniel M. Moreira | Further Details |
| 1629 | GSK | Assessing sex-differences and the effect of timing of vaccination on immunogenicity, reactogenicity and efficacy of vaccines in young children | University of Oxford | Merryn Voysey | Further Details |
| 1630 | GSK | A framework for individualized prediction of the rate and severity of asthma exacerbations | Faculty of Pharmaceutical Sciences and Faculty of Medicine, University of British Columbia | Mohsen Sadatsafavi | Further Details |
| 1633 | ViiV | Comparative effect of dolutegravir and raltegravir on CD4+/CD8+ ratio, CD4%, and multiple T-cell marker recovery. SPRING-2 study. | Hospital San Pedro - Center for Biomedical Research of La Rioja (CIBIR), SPAIN | Jose Ramon Blanco | Further Details |
| 1637 | Novartis | 1618 - Optimizing Patient Reported Outcomes by Linking Study Endpoints to Real-World Benchmarks | University at Buffalo, SUNY | Dr. Jeffrey Lackner | Further Details |
| 1640 | GSK | Effect of Fluticasone/Salmeterol on Chronic Bronchitis Symptoms and Associated Patient Reported Outcomes: a post-hoc analysis of the TORCH trial | Lewis Katz School of Medicine, Temple University. | Victor Kim | Further Details |
| 1643 | Astellas, Lilly, Novartis, Roche | Development of an accurate statistical method for evaluating region-specific treatment effects in multiregional clinical trials | The Institute of Statistical Mathematics, Research Organization of Information and Systems, Tokyo, Japan | Hisashi Noma | Further Details |
| 1646 | Lilly | Effects of tumor burden change (response) on survival in mesothelioma | Mayo Clinic | Aaron Mansfield | Further Details |
| 1654 | GSK, Lilly | Placebo Response in Major Depressive Disorder. | University of California, Los Angeles | Ariana Anderson | Further Details |
| 1660 | Sanofi | Assessing the generalizability of all-cause mortality from the MOSAIC trial to older adults diagnosed with stage II and III colon cancer in SEER-Medicare | University of North Carolina at Chapel Hill, Department of Epidemiology, Gillings School of Global Public Health | Jennifer L. Lund | Further Details |
| 1668 | Roche | Quantitative Evaluation of Circadian Rhythm of Serum Glucose Level in Caucasian and Chinese Type 2 Diabetic Patients (Oct/2016) | Phase I Unit, Clinical Pharmacology Research Center, Peking Union Medical College Hospital | Pei Hu | Further Details |
| 1675 | Lilly | Efficacy and tolerability of SNRIs in depression. | Department of Pharmacology, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden | Elias Eriksson | Further Details |
| 1684 | Roche | ANSELMA
Antiangiogenic agents in advanced non-small cell lung cancer patients who failed first-line chemotherapy: an individual patient data meta-analysis | Gustave Roussy | BENJAMIN BESSE | Further Details |
| 1688 | Novartis | Translational data from LPT109096 to assess the impact of HER2-targeted therapies on HER-family and stem cell marker expression. | National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland. | Denis Collins | Further Details |
| 1691 | GSK | Longitudinal Concurrent and Predictive Biomarkers of Clinical Disease Severity in Systemic Lupus Erythematosus in BLISS-52/BLISS-76 | Pfizer | Austin Huang | Further Details |
| 1692 | Boehringer Ingelheim, GSK | Predictors of chronic obstructive pulmonary disease progression | Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba university, Chiba, Japan | Akihiro Hisaka | Further Details |
| 1693 | Lilly, Novartis | Identifying Subgroups of Response to Biologics in Psoriasis using Large-scale Patient-level Data | University of Manchester | Nophar Geifman | Further Details |
| 1695 | GSK | Outcome measures and baseline predictors of response to belimumab treatment. | Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden | Ioannis Parodis | Further Details |
| 1702 | Roche | Pooled analysis of cardiac safety of T-DM1 in HER2-positive metastatic breast cancer patients | Institut Jules Bordet
BrEAST Data Center, Brussels Belgium | Evandro de Azambuja | Further Details |
| 1707 | Lilly | Comparative Effectiveness Analysis with Data From Randomized Clinical Trials and Observational Studies | The University of Hong Kong
Duke University (Adjunct) | Herbert Pang | Further Details |
| 1721 | Lilly, Roche | Improving the evaluation of new cancer therapies to expedite patient access | University of Adelaide | Professor Jonathan Karnon | Further Details |
| 1726 | Takeda, UCB | Association Between Obesity and Response to Biologic Therapy in Inflammatory Bowel Diseases | University of California San Diego | Siddharth Singh | Further Details |
| 1731 | GSK | Host characteristics impacting Rotarix immunogenicity and correlates of protection for rotavirus gastroenteritis, a multi-site pooled analysis of individual-level clinical trial data | Department of Epidemiology, Rollins School of Public Health, Emory University | Julia M. Baker | Further Details |
| 1732 | Astellas, Boehringer Ingelheim, GSK, Lilly, Novartis, Roche, Sanofi, Takeda, UCB | Assessing heterogeneity in relative treatment efficacy by age, sex and comorbidity. | University of Glasgow | Dr David A McAllister | Further Details |
| 1733 | Roche | Identifying Trajectories of Disease Activity States in Juvenile Idiopathic Arthritis (JIA) Early After Treatment: Shortening Time to Decision to Change Treatment | Rady Faculty of Health Sciences, University of Manitoba
Children's Hospital Research Institute of Manitoba, University of Manitoba | Lily Lim | Further Details |
| 1741 | Lilly | Predictors of exposure, therapeutic and adverse effects of drugs used in the treatment of advanced breast cancer and advanced colorectal cancer. | Flinders University | Dr Ashley Mark Hopkins | Further Details |
| 1749 | GSK, Novartis, Roche | Bisphosphonates for the Treatment of Osteoporosis In Chronic Kidney Disease: an Individual Patient Level Systematic Review and Meta-Analyses | Division of Nephrology, Department of Medicine, McMaster University, Department of Health Research Methods, Evidence and Impact, affiliated to Research St. Joseph's - Hamilton | Dr. David Collister | Further Details |
| 1752 | GSK | Sex Differences in responses to umeclidinium-vilanterol treatment in COPD patients | Istituto superiore di sanità, Italy | Elisabetta Straface | Further Details |
| 1758 | Novartis | Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of Chronic Kidney Disease | Tufts Medical Center/Tufts Medical School | Lesley A. Inker, MD | Further Details |
| 1764 | Sanofi, Takeda | Personalized Medicine Model Builder and Evaluation for Diabetes Treatments | Queens College, CUNY and the Wharton Business School of the University of Pennsylvania | Adam Kapelner | Further Details |
| 1779 | GSK | Evaluation of the effect of inhaled corticosteroids (ICS) on blood eosinophil count (EOS) in patients with COPD | Division of Infection, Immunity and Respiratory Medicine
University of Manchester, UK | Professor Jørgen Vestbo DMSc FRCP FERS | Further Details |
| 1786 | Lilly, Novartis, UCB | The efficacy of biologic medications in improving depressive symptoms in patients with psoriasis and PsA – Patient-level meta-analysis of randomized clinical trials data | University of Toronto, Women's College Hospital, Toronto, ON, Canada | Dr Lihi Eder | Further Details |
| 1794 | Roche | A study to identify the associated factor of reported adverse event severity among HER2-positive metastatic breast cancer patient from clinical trials. | Centre for Investigational New Product, National Pharmaceutical Regulatory Agency (NPRA) Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia | OH CHEN WEI | Further Details |
| 1808 | Roche, UCB | Long-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysis | Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal. | José A. P. da Silva | Further Details |
| 1813 | Takeda, UCB | Comparative efficacy of biologics in resolving extraintestinal manifestations of inflammatory bowel disease (IBD): a systematic review and meta-analysis | Mayo Clinic | Purna C. Kashyap, MBBS | Further Details |
| 1816 | Lilly, Roche | Individual patients data based meta-analysis of randomized trials assessing the interest of molecularly targeted treatments of advanced/recurrent stomach cancer:
A meta-analysis by the GASTRIC group | Gustave Roussy Cancer Center
Biostatistics and epidemiology dpt
INSERM CESP U1018 OncoStat
Meta-analysis platform
114 rue Ed Vaillant 94805 Villejuif cedex, France | Xavier Paoletti | Further Details |
| 1819 | GSK | INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF ANTIDEPRESSANT TRIALS FOR MAJOR DEPRESSION IN JAPAN | Hiroshima University | Shigeto Yamawaki | Further Details |
| 1831 | GSK, Novartis, Takeda | Statistical Methods Research to Compare the Performance of New Estimators of the Treatment Effect in Alzheimer’s Disease Randomized Trials | Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University | Michael Rosenblum | Further Details |
| 1843 | GSK | The genetics of glycaemic response to GLP-1 receptor agonists in Type 2 diabetes | University of Dundee
Dundee
DD1 9SY | Ewan Pearson | Further Details |
| 1844 | GSK | Real World Effects of Medications for Chronic Obstructive Pulmonary Disease | London School of Hygiene & Tropical medicine (LSHTM) | Dr Kevin Wing | Further Details |
| 1847 | Sanofi | Antiangiogenic Second line Lung cancer Meta-Analysis (ANSELMA) - A meta-analysis on antiangiogenic agents in advanced non-small cell lung cancer patients who failed first-line chemotherapy. | University Paris-Sud and Gustave Roussy, Department of Medicine
114 Rue Edouard Vaillant, 94805 Villejuif Cedex, France
Phone: +33 (0)1 42 11 43 22
Fax: +33 (0)1 42 11 52 19 | Benjamin Besse | Further Details |
| 1851 | Roche | Validation of a Novel Outcome Instrument for SLE Clinical Trials Using Phase II Rontalizumab Study Data Set. | UCSD School of Medicine | Kenneth Kalunian | Further Details |
| 1857 | GSK, Novartis | Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia: a systematic review and individual patient data network meta-analysis | Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael’s Hospital | Andrea C. Tricco | Further Details |
| 1880 | Boehringer Ingelheim, Eisai, Lilly, Roche, Sanofi | Improving the evaluation of new cancer therapies to expedite patient access | University of Adelaide | Professor Jonathan Karnon | Further Details |
| 1907 | GSK | Critical characterization of the impact of clinical-pathological tumoral features on recurrence risk dynamics of NSCLS. | European institute of Oncology , Milan | Tommaso De Pas | Further Details |
| 1911 | Boehringer Ingelheim, Daiichi Sankyo | Lower incidence of atrial fibrillation in NOAC treated patients without prior AF | Department of Cardiology, Maastricht University Medical Centre, Maastricht, the Netherlands | Ömer Erküner | Further Details |
| 1925 | GSK | EstablishINg the best STEp-up treatments for children with uncontrolled asthma despite Inhaled corticosteroids (EINSTEIN): A systematic review, network meta-analysis and cost effectiveness analysis | University of Liverpool | Catrin Tudur Smith | Further Details |
| 1928 | GSK | The development of a disease progression model to describe the long-term effects of anti-diabetic medications on Hemoglobin A1C | The University of Jordan | Mohammad Saleh | Further Details |
| 1933 | Novartis | Benefit-harm assessment of Fingolimod: a novel methodology to inform patients with MS, industry, guideline developers and regulatory agencies on the balance of benefits and harms | University of Zurich
Institute of Social and Preventive Medicine
Hirschengraben 84
CH-8001 Zurich | Alessandra Spanu | Further Details |
| 1934 | GSK | Using zanamivir trial data to evaluate baseline characteristics and disease progression by various subgroups to inform clinical development of novel therapies in hospitalized patients with influenza | Genentech, Inc., A member of the Roche Group | Lesley Butler | Further Details |
| 1955 | Boehringer Ingelheim | Development and validation of a model to predict absolute vascular risk reduction due to intensive blood-pressure targets in individual patients at baseline and after three months | University Medical Center Utrecht, Utrecht, the Netherlands | F.L.J. Visseren | Further Details |
| 1973 | Roche | The Role of Targeted Agents and Their Effects on Lymphocytes and Patient Outcomes | Investigational Drug Branch Cancer Therapy Evaluation Program Division of Cancer Treatment and Diagnosis National Cancer Institute | Elad Sharon | Further Details |
| 1996 | Sanofi | Statistical Methods for Causal Inference Adjusting for Adherence | Southern Methodist University Department of Statistics
University of Texas Southwestern Medical Center Department of Clinical Sciences | Daniel Heitjan | Further Details |
| 2029 | GSK | Matching the Right Antidepressants with the Right Patients: Using Artificial Intelligence to Personalize the Treatment of Depression | Douglas Mental Health University Institute McGill University | Gustavo Turecki | Further Details |
| 2033 | Boehringer Ingelheim | Applying machine learning tools to personalize dabigatran treatment decisions | Stanford University | Sanjay Basu | Further Details |
| 2036 | Boehringer Ingelheim | Prediction of bleeding events in patients with non-valvular atrial fibrillation - validation of the VTE-BLEED score | Leiden University Medical Centre, Leiden, Netherlands | Menno V Huisman | Further Details |
| 2056 | Lilly | Breakthrough on Antipsychotic Maintenance Medication: An Individual Participant Data Meta-Analysis. | The Zucker Hillside Hospital,
The Feinstein Institute of Biomedical Research
Northwell Health | Jose M Rubio M.D. | Further Details |
| 2069 | Lilly | Estimating the impact of different approaches to the analysis of time-to-event and longitudinal data on modelled cost-effectiveness. | School of Health and Related Research (ScHARR), The University of Sheffield | Ben Kearns | Further Details |
| 2074 | Roche | Association between pertuzumab induced diarrhea and cutaneous rash and survival outcomes in patients with HER2-positive metastatic breast cancer enrolled in the CLEOPATRA trial | Institut Jules Bordet | Evandro de Azambuja | Further Details |
| 2082 | GSK | Assessing the difference in results of aggregate data meta-analysis and individual patient data meta-analysis | Birla Institute of Technology, Mesra | Diwakar Jha | Further Details |
| 2084 | GSK | Relationship between plasma levels of a1-Antitrypsin levels and the severity of airflow limitation | Pneumology Department. Hospital Universitari Vall d'Hebron. Barcelona, Spain | Marc Miravitlles | Further Details |
| 2085 | GSK | Identify Systemic Lupus Erythematosus (SLE) Patients Treated with Belimumab with Reduced Severe and Severe/Moderate Flares: A Post-hoc Trial Analysis | Johns Hopkins University
Bloomberg School of Public Health
Department of Health Policy and Management
Center for Drug Safety and Effectiveness
Center for Population Health IT | Hongjun Kan | Further Details |
| 2087 | Lilly | Effectiveness of rhGH in Children with GHD in GeNeSIS (NCT01088412) - revised | Founder and Chief Scientific Officer, Ammonett Pharma
Retired from University of Virginia after serving on faculty for 40 years as a clinical investigator, Division Chief Endocrinology and Metabolism, Chairman of the Department of Medicine | Michael O. Thorner | Further Details |
| 2099 | Boehringer Ingelheim | Blood pressure variability in PRoFESS and development of incident stroke | University of Utah, Department of Neurology | Adam de Havenon | Further Details |
| 2100 | GSK | Review of post-vaccination fever and antipyretic use and their relation to vaccine immunogenicity after quadrivalent influenza vaccine in children. | National Centre for Immunisation Research and Surveillance, The Children's Hospital at Westmead | Dr Jean Li-Kim-Moy | Further Details |
| 2110 | Lilly | Effects of tumor burden change (response) on survival in mesothelioma | Mayo Clinic | Aaron Mansfield | Further Details |
| 5453 | Roche | Evaluation of Postmastectomy Radiotherapy in Women with HER-2 positive Breast Cancer | American University of Beirut, Medical Center | Youssef Zeidan | Further Details |
| 5459 | GSK | Placebo Effects in Asthma Randomized Clinical Trials: Their Magnitudes, Causes and Potential for Improving Care | The Ottawa Hospital Research Institute, University of Ottawa | Shawn D. Aaron | Further Details |
| 5460 | GSK | The evaluation of hemagglutination-inhibition antibody titer as a mediator of vaccine-induced protection against laboratory-confirmed influenza infections | School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong. | Prof Benjamin J Cowling | Further Details |
| 5471 | GSK | Evaluating predictors of antidepressant response or remission in children and adolescents with depression | University of Maryland Baltimore, School of Pharmacy, Pharmaceutical Health Services Research Department | O'Mareen Spence, MPH | Further Details |
| 5494 | Sanofi | Improving Colon Cancer Therapy Decisions by Extending Trial Representation | Department of Epidemiology, University of North Carolina at Chapel Hill | Jennifer Lund | Further Details |
| 5495 | Boehringer Ingelheim | Applying clinical trial results in clinical decision-making: Impact of a patien's baseline risk on the relative effect of an intervention strategy. | University Medical Center Utrecht, Utrecht, the Netherlands | Frank L.J. Visseren | Further Details |
| 5499 | Roche | Incorporating biomarkers into survival models to predict patient | Rutgers University | Dr. Luigi Brunetti, PharmD, MPH | Further Details |
| 5501 | Roche | Efficacy and Tolerability of Trastuzumab-Emtansine in Elderly Patients with Advanced Breast Cancer; A Combined Analysis | Institut Jules Bordet | Noam Pondé | Further Details |
| 5502 | Lilly | Health Determinants of the quality of life among children with ADHD: a structural equation modelling approach | National Research Council, Neuroscience Institute, Padova, Italy | Nadia Minicuci | Further Details |
| 5504 | Boehringer Ingelheim | Estimating Oral Anticoagulant Comparative Effectiveness in the Setting of Effect Heterogeneity: Comparing Clinical Trial Transport and Observational Epidemiologic Methods | University of North Carolina at Chapel Hill | Michael Webster-Clark | Further Details |
| 5505 | Boehringer Ingelheim, Lilly | A Data-Driven Statistical/Machine Learning Analysis for Extracting Clinically Actionable Predictions of Antidepressant Treatment Outcomes with Individual Depressive Symptoms | Mayo Clinic, Dept. of Psychiatry and Psychology | William V. Bobo | Further Details |
| 5506 | Lilly | Development of a limited sampling strategy for pharmacokinetic studies with pemetrexed. | Radboud University Medical Center | Rob ter Heine | Further Details |
| 5509 | Boehringer Ingelheim | Statistical methodology for the analysis of incomplete data in non-inferiority clinical trials. | University of Connecticut, Department of Statistics, CT, USA | Yulia Sidi | Further Details |
| 5513 | Lilly, Novartis | Association of sunlight intensity with Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms and interactions with pharmacological treatment: A cross-sectional approach. | Research Institute Brainclinics, Nijmegen, The Netherlands Utrecht University, Dept. of Experimental Psychology, Utrecht, The Netherlands | Martijn Arns | Further Details |
| 5515 | GSK | Impact of HPV16/18 vaccine on HPV genotype infection and cervical precancerous lesions: an implication for cervical cancer screening strategy | National Cancer Center & Cancer Hospital, Chinese Academy of Medical Sciences | Fanghui Zhao | Further Details |
| 5521 | GSK | Impact of HPV vaccination in preventing subsequent infection and disease after excision treatment | National Cancer Center & Cancer Hospital, Chinese Academy of Medical Sciences | Fanghui Zhao | Further Details |
| 5525 | GSK | Novel approaches for the analysis of SLE clinical trials | Albert Einstein College of Medicine | Mimi Kim | Further Details |
| 5528 | Boehringer Ingelheim | Spirometric Z-Score Reappraisal of the UPLIFT Trial: A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease | Yale University School of Medicine | Carlos A. Vaz Fragoso, MD | Further Details |
| 5548 | Boehringer Ingelheim, Lilly, Roche | Predictors of exposure, therapeutic and adverse effects of targeted therapeutics used in the treatment of lung cancer. | Flinders University | Ashley Hopkins | Further Details |
| 5549 | Boehringer Ingelheim, GSK | Model-based meta-analysis of anticoagulant therapy based on individual patient data | Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan | Hisaka Akihiro | Further Details |
| 5565 | Eisai | Predictors of exposure, therapeutic and adverse effects of lenvatinib used in the treatment of advanced thyroid cancer. | Flinders University | Ashley Hopkins | Further Details |
| 5567 | Lilly | PROCLAIM trial secondary analysis: Request for data to determine pre- and mid-treatment neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratios and lymphocyte nadir values to analyze if they are predictive of survival outcome. | University Hospitals Siedman Cancer Center, Case Western Reserve University, Cleveland, OH | Tithi Biswas | Further Details |
| 5602 | Roche | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers. | Flinders University | Ashley Hopkins | Further Details |
| 5625 | Roche | Investigating the effects of rituximab on specific cell subsets and cytokine levels in systemic lupus erythematosus patients and constructing a prediction model of treatment response | Stanford University | Matthew Baker | Further Details |
| 5642 | GSK | FEV1 decline across BMI gradient in COPD patients who were part of large randomized controlled trial over at least 3 years. | Centre for Heart Lung Innovation, St Paul's Hospital and Division of Respiratory Medicine, University of British Columbia,Vancouver, BC V6Z 1Y6, Canada | Don D Sin | Further Details |
| 5644 | GSK, Lilly, Sunovion | Factor analysis using the Generalisability Theory of PANSS data from clinical trials in schizophrenia and bipolar disorder | University Hospital Geelong, Barwon Health, Geelong, Australia | Seetal Dodd | Further Details |
| 5652 | UCB | Efficacy of Crohn's Disease Treatment Stratified by Disease Phenotype | University of California - San Francisco | Vivek Rudrapatna | Further Details |
| 5655 | Astellas, Bayer, Boehringer Ingelheim, GSK, Lilly, Roche, Sanofi, Takeda, ViiV | Prediction of recruitment in randomized clinical trials (RECRUIT-IT) | Department of Medical Oncology & Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland | Kasenda Benjamin | Further Details |
| 5658 | GSK | Does Shingrix vaccination reduces the risk of stroke? | University of Antwerp & Antwerp University Hospital | Benson Ogunjimi | Further Details |
| 5742 | Boehringer Ingelheim, GSK, Novartis | Comparison of the effects of dual and single bronchodilators in COPD patients relocated from group D to group B by the revised 2017 GOLD classification: a post-hoc pooled analysis of global RCTs | Professor, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea Head, the Department of Pulmonary and Critical Care Medicine, Asan Medical Center, Seoul, South Korea | Yeon-Mok Oh | Further Details |
| 5758 | Roche | Predicting the real world effectiveness and safety of medical interventions | Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland | Orestis Efthimiou | Further Details |
| 5769 | GSK | The risk of recurrent Plasmodium vivax malaria and haematological effect of treatment with or without primaquine: a systematic review and individual patient data meta-analysis | Menzies School of Health Research, Darwin, Australia WorldWide Antimalarial Resistance Network (WWARN), University of Oxford, UK | Rob Commons | Further Details |
| 5775 | Roche | Early identification of immunotherapy response based on computational models | Applied Tumor Immunity (D120) National Center for Tumor Diseases (NCT) German Cancer Research Center (DKFZ) Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany Gastroenterology and Gastrointestinal Oncology University Hospital RWTH Aachen Pauwelsstraße 30, D-52074 Aachen, Germany | Jakob Nikolas Kather | Further Details |
| 5791 | Novartis | Trends of CRT therapy in heart failure patients with reduced ejection fraction on LCZ696 versus Enalapril | University of Miami | Abdullah Sarkar MD | Further Details |
| 5793 | Astellas, UCB | Predictors of exposure, therapeutic and adverse effects of certolizumab pegol used in the treatment of rheumatoid arthritis. | Australian Center for Pharmacometrics, School of Pharmacy and Medical Sciences, University of South Australia | Ahmad Y Abuhelwa | Further Details |
| 5796 | GSK, Lilly | Symptom level analysis of recovery during antidepressant treatment | Department of Psychology and Logopedics, Medical Faculty, University of Helsinki, Helsinki, Finland | Markus Jokela | Further Details |
| 5805 | GSK | Choosing the Right Antidepressant for Depression: Individual Patient Data Network Meta-Analysis | Department of Psychiatry, University of Oxford Oxford Health NHS Foundation Trust | Professor Andrea Cipriani | Further Details |
| 5806 | GSK | Melancholic depression and response to lamotrigine for the treatment of acute bipolar depression: a pooled analysis of five randomized controlled trials | Department of Psychiatry, College of Medicine, University of Saskatchewan | Dr. Evyn Peters | Further Details |
| 5807 | Lilly, Novartis, Roche | Predictors of exposure, therapeutic and adverse effects of medicines used in the treatment of breast cancer. | Flinders University | Ashley Hopkins | Further Details |
| 5808 | Roche | Effect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis | Leiden University Medical Center | Diane van der Woude | Further Details |
| 5809 | Roche | Effectiveness of anti HER2 blockade according to host immune status | Gangnam Severance Hospital Department of Surgery | Joon Jeong | Further Details |
| 5814 | UCB | Calculating the Ankylosing Spondylitis Disease Activity Score (ASDAS) in radiographic and non-radiographic axial spondyloarthritis when Patient Global Assessment (PGA) is not available | Leiden University Medical Center (LUMC) | Désirée van der Heijde | Further Details |
| 5815 | GSK | Examining statistical methods to allow comprehensive evaluation and presentation of adverse event data in randomised controlled trials | Imperial College London | Rachel Phillips | Further Details |
| 5819 | GSK | The immunogenicity and efficacy of pneumococcal vaccines: a systematic review and network meta-analysis of individual participant data | University of Oxford | Merryn Voysey | Further Details |
| 5835 | GSK | Combined effect of belimumab and hydroxychloroquine treatment : results from the phase 3 belimumab clinical trials in patients with SLE | Center of Research of Immunopathology and Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. | Savino Sciascia | Further Details |
| 5836 | Roche | Exploring possibilities to improve the risk:benefit balance through anlaysis of the ocrelizumab phase II extension study | Blizard Institute Barts and the London School of Medicine and Dentistry Queen Mary University of London 4 Newark Street London EC1 2AT | David Baker/Klaus Schmierer | Further Details |
| 5847 | GSK | Effectivity of Belimumab in arthritic and hematologic SLE manifestations | Dep. of Internal Medicine III Carl Gustav Carus Medical Center University of Dresden Germany | Nicolai Leuchten | Further Details |
| 5851 | Novartis | Statistical Methods for Analyzing KCCQ in Heart Failure Trials | Department of Mathematics & Statistics University of Maryland Baltimore County Baltimore, MD | DoHwan Park, Ph.D. | Further Details |
| 5855 | GSK | A clinical practice for detecting the phases of Herpes Zoster. | * Athens University of Economics and Business, Department of Statistics (www.stat-athens.aueb.gr ) * Frontier Science Foundation Hellas (www.frontier-science.gr ) | Dimitris Karlis | Further Details |
| 5862 | GSK | Impact of belimumab on antiphospholipid antibodies in patients with Systemic Lupus Erythematosus | 1st Department of Propaedeutic and Internal Medicine, Laiko Hospital, Medical School, National and Kapodistrian University of Athens, Greece | Katerina Chatzidionysiou | Further Details |
| 5865 | GSK | Hospitalized influenza clinical studies: benchmarking and refinement of clinical endpoints | Biomedical Advanced Research and Development Authority (BARDA) Office of the Assistant Secretary for Preparedness and Response (ASPR) Department of Health and Human Services (HHS) | Kimberly Armstrong | Further Details |
| 5880 | Roche | Assessing immune system correlates to individual tumour size dynamics | University of Manchester, Manchester, UK | Dr Hitesh Mistry | Further Details |
| 5881 | Novartis | Relationship between outcomes and systolic blood pressure reduction during the first 24 h in acute heart failure syndrome: an exploratory analysis of the Relax-AHF-studies | The University of Copenhagen, and the Department of Cardiology, Bispebjerg Hospital, 2400 Copenhagen NV, Denmark | Olav Wendelboe Nielsen | Further Details |
| 5886 | GSK | Efficacy of belimumab in patients with active systemic lupus erythematosus and concomitant antiphospholipid syndrome | Istituto Auxologico Italiano, IRCCS, Laboratory of Immunorheumatology, Milan, Italy. | Pier Luigi Meroni | Further Details |
| 5895 | ViiV | Pharmacogenetics of Interaction between Efavirenz and Dolutegravir | Vanderbilt University Medical Center Nashville, Tennessee | David W. Haas, MD | Further Details |
| 5904 | Lilly, Roche | Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer | Iowa State University | Benjamin K Schneider | Further Details |
| 5906 | UCB | Modelling seizure rates rather than time to an event within clinical trials of antiepileptic drugs | University of Liverpool | Laura Bonnett | Further Details |
| 5915 | GSK | SLE clinical and laboratory profiling to indentify best response to belimumab: results from the phase III belimumab clinical trials | Center of Research of Immunopathology and Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. MD, Consultant in Clinical Immunology | Savino Sciascia | Further Details |
| 5936 | Takeda, UCB | The impact of biological interventions on health-related quality of life in adults with Crohn's disease | UHC rijeka, krešimirova 42, 51000 Rijeka, Croatia | Mirjana Stanic Benic | Further Details |
| 5937 | Roche | Predictors of exposure, therapeutic and adverse effects of tocilizumab used in the treatment of rheumatoid arthritis. | University of South Australia | Ahmad Y Abuhelwa | Further Details |
| 5951 | Lilly | Alternative Data Presentation For Treatment Outcomes in Psoriasis | University of Alberta, Faculty of Medicine & Dentistry, Division of Dermatology, Canada | Robert Gniadeki | Further Details |
| 5979 | Lilly | Predictors of exposure, therapeutic and adverse effects of baricitinib used in the treatment of rheumatoid arthritis. | Australian Center for Pharmacometrics, School of Pharmacy and Medical Sciences, University of South Australia | Ahmad Y Abuhelwa | Further Details |
| 5981 | Roche | Multi-state models for the analysis of survival data in radiation therapy. | Department of Radiotherapy, Paoli Calmettes Institute, Marseille, France. | Pierre Annede | Further Details |
| 5988 | Lilly, Novartis, Roche | Pattern Extraction and Patient-Level Prediction of Adverse Events Using Meta-Analysis and Matrix Decomposition | Tokyo University of Science | Kentaro Matsuura | Further Details |
| 5995 | Novartis | An investigation of clinical outcome measures in PPMS to inform the design of investigator initiated clinical trials. | University of Calgary, Calgary, Alberta, Canada | Marcus Koch MD PhD | Further Details |
| 6001 | Lilly | Can I use machine learning to build a prediction model of individual patient outcome in first episode psychosis? | Institute of Mental Health & Wellbeing, University of Glasgow Honorary Specialty Registrar General Adult Psychiatry, NHS Greater Glasgow & Clyde | Dr Samuel Leighton | Further Details |
| 6009 | GSK | Examining Immune Setpoints in Children and Adults Who Received Multivalent Hepatitis B Vaccines | J. Craig Venter Institute (JCVI) | Yun Zhang | Further Details |
| 6042 | Astellas, Bayer, Eisai, GSK, Sanofi | An investigation into unblinded sample size re-estimation methodology in clinical trials | The University of Sheffield | Julia Edwards | Further Details |
| 6066 | Novartis | Evaluating the role of Clinical Study Reports, as unpublished sources of evidence for the use of sacubitril/valsartan in adults and its impact on evidence synthesis. | Department of General Practice and HRB Centre for Primary Care Research | Dr David Byrne | Further Details |
| 6078 | Novartis, Roche | Evaluation of Radiotherapy after Complete Response to Neoadjuvant Chemotherapy in HER-2 Positive Breast Cancer Patients | American University of Beirut, Medical Center | Youssef Zeidan | Further Details |
| 6080 | Roche | Exploratory Analysis of CRANE Influenza Study to Assess Impact of MHAA4549A among Subgroups Classified by Influenza Severity | Veristat | Robin Bliss | Further Details |
| 7080 | Roche, Sanofi | The clinical outcome based on the treatment course factors in CLASSIC trial. | Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan | Hisaka Akihiro | Further Details |
| 7082 | Roche | Evaluation of Radiotherapy Boost in Women with HER-2 positive Breast Cancer. | Department of Radiation Oncology, American University of Beirut Medical Center, Beirut, Lebanon. | Youssef Zeidan | Further Details |
| 8102 | GSK | Open Label Extension Analysis - Exploring Self-Controlled Case Series Methodology | London School of Hygiene and Tropical Medicine | Ian Douglas | Further Details |
| 9115 | GSK | inhaled STerOids for the Prevention of Lung Cancer. (STOP Lung Cancer) | Clínica Universidad de Navarra | Luis Seijo | Further Details |
| 9131 | GSK | Validation of the diabetes microsimulation model in the HARMONY trial | University of Florida College of Pharmacy | Hui Shao | Further Details |
| 9134 | ViiV | Population pharmacokinetic analysis of interaction between dolutegravir and rifampin | Department of Medicine University of Cape Town Health Sciences Faculty | Gary Maartens | Further Details |
| 9140 | Eisai | INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF DONEPEZIL FOR ALZHEIMER'S DISEASE | Kyoto University Graduate School of Medicine / School of Public health | Toshi A. Furukawa | Further Details |
| 10141 | GSK | Impact of rotavirus genotype and local rotavirus gastroenteritis incidence on Rotarix vaccine efficacy estimates: a multi-site pooled analysis of individual-level clinical trial data | Department of Epidemiology, Rollins School of Public Health, Emory University | Avnika B. Amin | Further Details |
| 10189 | Roche | Evaluation of Radiotherapy in Triple Negative Breast Cancer: Analysis of the BEATRICE trial | American University of Beirut, Medical Center | Youssef Zeidan | Further Details |
| 10195 | GSK | Relationship Between Baseline Blood Electrolyte Levels and Risk of Asthma Exacerbation | Gossamer Bio | Greg Opitek | Further Details |
| 10204 | Novartis | Validity of Renal Transplant Outcomes in the Australian and New Zealand Dialysis and Transplant Registry: Comparison with Clinical Trials Data | Employer: Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia Research Affiliation: University of Sydney, Sydney, NSW, Australia | Tracey Ying | Further Details |
| 11229 | GSK | Exploration of the Hospital Recovery Scale as an endpoint to assess clinical improvement in hospitalized influenza patients | Janssen R&D Belgium | Wilbert van Duijnhoven | Further Details |
| 11236 | GSK | Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) validation: post-hoc analysis of the BLISS-52 and BLISS-76 phase III trials. | Professor of Rheumatology and Head of the CHUC Lupus Clinic, Rheumatology Department, Centro Hospitalar e Universitário de Coimbra. Coimbra, Portugal Professor of Rheumatology at Faculty of Health Sciences, University of Beira Interior. Covilhã, Portugal | Luís Inês | Further Details |
| 11254 | GSK | Evaluation of the pharmacokinetics of valacyclovir in subjects 1 month of age or older in order to assist in the design of a safer, more beneficial study of its pharmacokinetics in neonates under 2 weeks of age. | University of Alabama at Birmingham | David Kimberlin, MD | Further Details |
| 11280 | GSK | Antibody response to primary and booster immunization in infants born to mothers immunized with pertussis-containing vaccines during pregnancy versus unimmunized women: a systematic review and meta-analysis | University of British Columbia, Canada | Dr. Manish Sadarangani | Further Details |
| 11283 | GSK | Association between Vaginal Infection and Cervical Non-HPV16/18 Infection in Women after Bivalent HPV Vaccination | Cancer Hospital, Chinese Academy of Medical Sciences | Fanghui Zhao | Further Details |
| 11298 | GSK | Development of personalised predictive models for the evolution of atopic dermatitis severity in response to treatment | Department of Bioengineering, Imperial College London | Reiko Tanaka | Further Details |
| 11302 | GSK | Assessment of the prognostic impact of including standard serological markers in the definitions of remission and low lupus disease activity in patients with SLE | University of Crete Medical School; University Hospital of Heraklion, Greece | George Bertsias | Further Details |
| 11340 | GSK | Towards precision medicine in Chronic Obstructive Pulmonary Diseases: predicting individual treatment response and general outcomes in SUMMIT | University Hospitals Leuven Department of Respiratory Diseases Research Laboratory BREATHE, Department CHROMETA, KU Leuven Herestraat 49 3000 Leuven Belgium | Wim Janssens | Further Details |
| 11384 | GSK | Human papillomavirus(HPV) vaccine efficacy and immunogenicity in women with existing HPV infections | National Cancer Center & Cancer Hospital,Chinese Academy of Medical Sciences | Fanghui Zhao | Further Details |
| 11435 | GSK | Natural history of human papillomavirus and associated lesions in healthy Chinese women | National Cancer Center & Cancer Hospital,Chinese Academy of Medical Sciences | Fanghui Zhao | Further Details |
| 11508 | Astellas, GSK, Sanofi | Three types of hypoglycemic agents (Dipeptidyl peptidase-4 inhibitors, Glucagon-like peptide-1 receptor agonists, Sodium-dependent glucose transporters 2 inhibitors) for patients with type 2 diabetes: effectiveness and safety evaluation network meta-analysis | School of Public Health, Peking University | Sun Feng | Further Details |
| 11567 | Astellas, GSK, Novartis | Proposal Title | Test Company of Lead Researcher | Test Lead Researcher | Further Details |